Figure S1

A.

| Day 0: Plate Cells | Day 1: siRNA Transfection | Day 2: Drug Treatment | Day 4: Viability Measurement |

323 siRNAs

323 siRNAs — DMSO

323 siRNAs

323 siRNAs — INC280

323 siRNAs

323 siRNAs — Erlotinib

→ CellTiter-Glo Analysis

Analysis

$$\text{Sensitivity Index} = \left(\frac{\text{RLE siRNA + DMSO}}{\text{Control siRNA + DMSO}} \times \frac{\text{Control siRNA + Drug}}{\text{Control siRNA + DMSO}} \right) - \left(\frac{\text{RLE siRNA + Drug}}{\text{Control siRNA + DMSO}} \right)$$

Transfectability

AllStars (blue), ACDC (red) — Percent Viability for HCC70, MDA-MB-231, MDA-MB-468, HS578t

C.

B.

Cell Line	TNBC Subtype	Source	Morphology	Mutations
hTERT-HME1	N/A	Immortalized Mammary Gland Epithelium	Epithelial	N/A
MDA-MB-231	Mesenchymal stem-like; Basal B	TNBC Metastatic	Epithelial	TP53; PDGFRA; NF2; BRAF
MDA-MB-468	Basal-like 1; Basal A	TNBC Metastatic	Epithelial	PTEN; ERBB2
Hs578T	Mesenchymal stem-like; Basal B	TNBC Metastatic	Epithelial	TP53; PIK3R1; NF1
HCC70	Basal-like 2; Basal A	TNBC Primary Ductal Carcinoma	Epithelial	TP53; RB1; PTEN; APC